ASCO 2024 Phase 3 IMROZ Results Evaluating Sarclisa (Isatuximab) + VRd in Transplant-Ineligible NDMM

Dr. Zandra Klippel summarizes Phase 3 results from the IMROZ study at ASCO 2024. This study evaluates the efficacy of Sarclisa (isatuximab) in combination with VRd (bortezomib, lenalidomide, and dexamethasone) in patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant.
More Details and Links Here: oncologytube.com/asco-2024-ph...
🔬 Key Points:
Study Objective: Assess the impact of adding Isatuximab to the VRd regimen on progression-free survival (PFS) and overall survival (OS).
Findings: The addition of Isatuximab significantly improved both depth of response and PFS, with a positive trend in OS.
Treatment Duration: Median treatment duration was 53 months for Isa-VRd versus 31 months for VRd alone, without compromising quality of life.
Subgroup Analysis: Consistent PFS benefits were observed across various subgroups, including different age ranges and risk profiles.
Safety Profile: No unexpected adverse events were noted, with manageable cytopenias and liver abnormalities.
Future Directions: Ongoing research aims to optimize dosing, reduce side effects, and expand the use of Isa-VRd to other myeloma populations, including those eligible for transplant.
🔗 Watch the full presentation for detailed insights into these promising findings and their implications for the treatment of transplant-ineligible NDMM patients. Don't forget to like, share, and subscribe for more updates from ASCO 2024!
#ASCO2024 #MultipleMyeloma #CancerResearch #Sarclisa #VRd #Oncology #MedicalResearch #DrZandraKlippel #TransplantIneligible #NDMM #ClinicalTrials